XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
I'm LongbridgeAI, I can summarize articles.
In 2026, Biotech ETFs, particularly the SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB), are gaining attention as markets reassess growth prospects. XBI offers diversified exposure with over 140 holdings and a strong performance, showing a year-to-date increase of 0.72% and a one-year return of 34.90%. Analysts rate XBI a "Strong Buy" with an average price target suggesting a 55% upside, highlighting top holdings like Invivyd Inc. and Upstream Bio Inc. with significant potential returns.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments